{"id":"NCT00856973","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia","officialTitle":"A Randomized, Placebo Controlled, Double Blind, Fixed Dose Study of the Efficacy and Safety of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2009-03-06","resultsPosted":"2013-04-10","lastUpdate":"2013-06-17"},"enrollment":486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Insomnia","Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"eszopiclone","otherNames":[]},{"type":"DRUG","name":"eszopiclone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Low dose eszopiclone","type":"EXPERIMENTAL"},{"label":"High dose eszopiclone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.","primaryOutcome":{"measure":"Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).","timeFrame":"Baseline (Day 0) to Week 12","effectByArm":[{"arm":"Pooled High Dose Eszopiclone","deltaMin":-18.33,"sd":3.91},{"arm":"Pooled Low Dose Eszopiclone","deltaMin":-23.45,"sd":3.91},{"arm":"Placebo","deltaMin":-25.66,"sd":3.92}],"pValues":[{"comp":"OG000 vs OG002","p":">0.05"},{"comp":"OG001 vs OG002","p":">0.05"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":14},"locations":{"siteCount":73,"countries":["United States"]},"refs":{"pmids":["25266438"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":159},"commonTop":["Headache","Dysgeusia","Upper respiratory tract infection","Dizziness","Nasopharyngitis"]}}